Journal of Clinical Oncology
Articles in this Issue
Trends in liver cancer mortality in the United States (2010–2021): A call for focused public health strategies.
e22534 Background: Liver cancer is the third leading cause of cancer-related mortality globally, contributing to 4.6% of all cancer deaths in the United S...
Effect of cell proliferation pathway on accessibility to targeted therapeutics in the spectrum of co-occurring prognostic cellular pathways in pan-cancers.
e15092 Background: Cellular pathways play a crucial role in prognosis and development of targeted therapies by impacting molecular mechanisms underlying d...
VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer.
TPS5112 Background: 177 Lu-PSMA-617 (LuPSMA), a prostate specific membrane antigen (PSMA) targeting radioligand therapy, is approved for men w...
Sinusoidal obstruction syndrome and other outcomes in pediatric patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin before hematopoietic cell transplantation.
e22000 Background: Inotuzumab ozogamicin (InO) is FDA approved for adult and pediatric (≥1 y) patients (pts) with relapsed/refractory (R/R) B-cell precurs...
The Vanguard study: An NCI cancer screening research network multi-cancer detection feasibility study.
e22522 Background: Multi-cancer detection (MCD) tests are promising; however, large-scale trials are needed to establish their harms, benefits, and clinic...
Effect of adverse outcomes—septicemias, healthcare complications, coagulopathies, and cardiac arrhythmias—on the burden of illness and related disparities among hospitalized cervical cancer patients afflicted by COVID-19.
e17524 Background: Cervical cancer patients receiving cancer care are at significant risk of adverse health outcomes, specifically when compounded by co-o...
Community-based patient navigation and preventative care among women surviving breast cancer.
1602 Background: Routine physical exams, mammograms, and Pap smears are essential to long-term follow-up for breast cancer survivors, enabling detection o...
Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders.
7010 Background: New therapies are needed for patients with relapsed or refractory (r/r) CLL/SLL following covalent and/or non-covalent BTK inhibitors. Wh...
Challenges in HIV-diffuse large B-cell lymphoma in Afro-Caribbean patients in a NYC hospital.
e19054 Background: Diffuse large B-cell lymphoma (DLBCL) remains a prominent cause of cancer-related mortality among HIV-infected individuals, even in the...
OncoPRO: A US national initiative supporting implementation of remote symptom monitoring with electronic patient-reported outcomes (ePROs) in oncology practices.
11138 Background: Remote symptom monitoring using electronic patient-reported outcomes (ePROs) results in improved symptom management, communication, qual...
Developing a simple outpatient prognostic model for prediction of survival in patients with advanced cancer.
e13871 Background: Predicting the life expectancy in patients with advanced cancer is important but difficult. Patients and families need a reasonably acc...
COBRA: Assessment of the efficacy of <sup>64</sup> Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
5102 Background: Accurate staging of recurrent prostate cancer (PC) is essential to inform the best treatment strategy. 64 Cu-SAR-...
Molecular alterations identified in a phase 1 study of fostamatinib plus paclitaxel in platinum-resistant ovarian cancer.
e17609 Background: Resistance to chemotherapy remains a challenge in recurrent platinum-resistant ovarian cancer (PROC). While the spleen tyrosine kinase...
Safety, efficacy, and biomarker analysis from a phase II trial of intensive chemotherapy combined with serplulimab and trastuzumab in patients with advanced HER2-positive gastric cancer.
4031 Background: Keynote-811 has proven the efficacy of combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastric cancer. Our study aims...
Implementing a multicomponent navigation program to reduce time intervals to treatment initiation for advanced breast cancer in Paraguay.
e13508 Background: Patient navigation programs have been associated to increase timely access to treatments and improved follow-up care in multiple diseas...
Real-world study on the application of FGFR inhibitors in metastatic bladder cancer: A multinational analysis.
e23306 Background: Metastatic urothelial cancer is an aggressive disease with a poor prognosis. Recent advances in the molecular characterization of uroth...
Potential of tumor-informed ctDNA as an early predictive indicator for relapse in advanced ovarian cancer.
5574 Background: Prediction of relapse following firstline treatment in patients (pts) with high-grade serous ovarian cancer (HGSOC) remains a major chall...
Comparison of the tolerability and safety of hedgehog inhibitors in real-life: A cohort of 330 patients with locally advanced basal cell carcinoma.
9583 Background: Two hedgehog pathway inhibitors (HHIs) have been approved for the treatment of locally advanced basal cell carcinoma (laBCC): vismodegib...
Role of hospital-based cancer registry in planning the cancer control program in semiurban setting in Alandi, Pune, Maharashtra, India.
e22566 Background: Indrayani Hospital and Cancer Institute (IHCI) in Maharashtra, India, has provided comprehensive cancer care to underserved populations...
Incidence of venous thromboembolism (VTE) events in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab: A systematic review and combined meta-analysis of phase 3 randomized controlled trials.
12042 Background: Amivantamab is a bispecific antibody that was granted accelerated approval by the FDA in May 2021 for the treatment of non-small cell lu...
Temporal trends in the incidence of Hodgkin's lymphoma in the Middle East and North Africa over the past three decades.
e19041 Background: Hodgkin lymphoma (HL) is a rare yet important hematologic malignancy of B-cell origin. While global incidence rates vary, the epidemiol...
Circulating free DNA derived from active chromatin as a predictive biomarker for clinical benefit to checkpoint inhibitor-based therapies in metastatic leiomyosarcoma.
11539 Background: Leiomyosarcoma (LMS) is a common subtype of soft tissue sarcoma with a poor prognosis in the metastatic setting. LMS shows minimal benef...
Assessing biosimilar entry in the market for biologic cancer drugs.
11162 Background: Biosimilars are biological drugs highly similar to and without clinically meaningful differences from their biological reference product...
Incidence rates of liver and intrahepatic bile duct cancers in young Hispanic populations: An exploratory study of the SEER database, 2017-2021.
e22539 Background: Liver & intrahepatic bile duct cancers rank 6th in U.S. cancer-related deaths. Prior studies have shown rising incidence of cancers...
The role of lipid-laden Kupffer cells in immunosuppression and immunotherapy response in MASLD-related hepatocellular carcinoma.
2568 Background: Hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising global health burd...